Internal Medicine, Hematology & Oncology · Van Nuys, CA
NPI
1487846416
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
15211 Vanowen St Ste 300
Van Nuys, CA, 91405
Phone (818) 782-4104
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.3M
51,562 services
Medicare patients, 2024
300
Average age 72
Drug cost, 2024
$8.2M
2,120 prescriptions
Company payments, 2025
$6,061
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sheila Vasan was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 1,995 times for 26 patients. In total Sheila Vasan billed 51,562 services in 90 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-06-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,995 | 26 | $0.09 | $179 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 868 | 15 | $0.08 | $65.53 |
| 99214 Office E&M - Established | Office | 681 | 225 | $98.65 | $67K |
| Q5101 Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | Office | 557 | 11 | $0.22 | $121 |
| 96127 Behavioral Health Services | Office | 333 | 207 | $3.53 | $1,176 |
| 96372 Injection Administration | Office | 258 | 34 | $12.38 | $3,194 |
| 99232 Hospital E&M - Subsequent | Facility | 159 | 25 | $64.95 | $10K |
| 96413 Chemotherapy Administration | Office | 143 | 25 | $109.94 | $16K |
| 96367 Intravenous Infusion, Hydration | Office | 134 | 26 | $23.01 | $3,083 |
| 85025 Blood Count | Office | 124 | 28 | $7.61 | $944 |
| 99233 Hospital E&M - Subsequent | Facility | 120 | 33 | $94.18 | $11K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 99 | 24 | $0.64 | $63.83 |
| 36415 Venipuncture Blood Collection | Office | 98 | 30 | $8.63 | $846 |
| J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) | Office | 91 | 23 | $1.04 | $94.34 |
| 96365 Intravenous Infusion, Hydration | Office | 67 | 18 | $53.24 | $3,567 |
By year: 2022 $476K for 34,576 services; 2023 $651K for 26,937 services; 2024 $1.3M for 51,562 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 124 | 28 | $7.61 | $944 |
| 36415 Venipuncture Blood Collection | 98 | 30 | $8.63 | $846 |
Medicare prescription drug claims, 2024
In 2024, the drug Sheila Vasan prescribed most often to Medicare patients was Anastrozole, with 160 prescriptions and refills. In total Sheila Vasan wrote 2,120 Medicare prescriptions that cost $8.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 160 | 332 | 40 | $2,527 |
| Procrit Epoetin Alfa | 95 | 95 | 24 | $292K |
| Letrozole Generic | 82 | 155 | 17 | $1,612 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 81 | 81 | 22 | $2,715 |
| Alendronate Sodium Generic | 75 | 149 | 22 | $455 |
| Eliquis Apixaban | 74 | 89 | 16 | $48K |
| Zarxio Filgrastim-Sndz | 72 | 72 | 23 | $62K |
| Jakafi Ruxolitinib Phosphate | 68 | 68 | Under 11 | $1.0M |
| Ondansetron Hcl Generic | 67 | 67 | 35 | $1,820 |
| Imatinib Mesylate Generic | 61 | 61 | Under 11 | $58K |
| Revlimid Lenalidomide | 58 | 58 | Under 11 | $889K |
| Dexamethasone Generic | 53 | 69 | 25 | $1,605 |
| Imbruvica Ibrutinib | 42 | 42 | Under 11 | $682K |
| Prednisone Generic | 40 | 49 | 17 | $215 |
| Keytruda Pembrolizumab | 38 | 40 | Under 11 | $591K |
Brand drugs: 876 claims; generic drugs: 1,244 claims; opioid claims: 117.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sheila Vasan $6,061 ($6,061 in general payments such as food, travel and fees) from 50 companies. The largest payer was Novartis Pharmaceuticals Corporation with $786.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 20 | $786 |
| AstraZeneca Pharmaceuticals LP AZN | 19 | $488 |
| Merck Sharp & Dohme LLC MRK | 13 | $349 |
| Incyte Corporation INCY | 10 | $338 |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $263 |
| Caris MPI, Inc. | 3 | $239 |
| Pfizer Inc. PFE | 8 | $200 |
| Eisai Inc. 4523.T | 11 | $200 |
| Gilead Sciences, Inc. GILD | 10 | $197 |
| Janssen Biotech, Inc. JNJ | 9 | $185 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.